Security Snapshot

Dare Bioscience, Inc. - Common Stock, $0.0001 par value (DARE) Institutional Ownership

CUSIP: 23666P200

13F Institutional Holders and Ownership History from Q2 2024 to Q3 2026

13F reference period

Q2 2026

Institutions Reporting

27

Shares (Excl. Options)

1.3MFull value: 1,301,754 · shares · 30 Jun 2026

Price

$2.11

The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Security type / class
Equity / Common Stock, $0.0001 par value
Symbol
DARE on Nasdaq
All holders as of 30 Jun 2026
Q2 2026
Total 13F shares
1,301,754
Latest holder snapshot 5 signals
Total 13F value
$2,748,180
Portfolio coverage rank
0%
Share change
+276,991
Value change
+$603,436
Number of holders
27
Issuer context Names, identifiers, and filing context for this profile. 2 identity fields
Shares outstanding
19,378,584
SEC-reported price per share
$0.75
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • DARE - Dare Bioscience, Inc. - Common Stock, $0.0001 par value is tracked under CUSIP 23666P200.
  • 27 institutions reported positions in Q2 2026.
  • 2 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 24 to 27 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from
    $1.87MFull value: $1,866,248 · USD · 31 Mar 2026
    to
    $2.75MFull value: $2,748,180 · USD · 30 Jun 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 27 institutions filings for Q2 2026.

Open SEC evidence

Security key

23666P200

13F reference period

Q2 2026

13F holders

27

13D/G owners

2

CIK / CUSIP context first

Open Q2 2026 holders DARE full holder history Dare Bioscience, Inc. SEC filings Dare Bioscience, Inc. company facts Dare Bioscience, Inc. insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
2
Security
DARE
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
L1 Capital Global Opportunities Master Fund, Ltd. 10% $2,596,973 2,028,885 L1 Capital Global Opportunities Master Fund, Ltd. 17 Aug 2026
Lind Global Fund III LP 5.6% $1,401,459 1,094,890 Lind Global Fund III LP 17 Aug 2026
As of 30 Jun 2026, 27 institutional investors reported holding
1.3MFull value: 1,301,754 · shares · 30 Jun 2026
shares of Dare Bioscience, Inc. - Common Stock, $0.0001 par value (DARE). This represents 6.7% of the company’s total
19.38MFull value: 19,378,584 · shares · Stored outstanding share count
outstanding shares.

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
10
Headline period
Q2 2026
Rows shown
1-10 of 10
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 27,397 $23,378 +$13,870 $0.85 8
2026 Q2 1,301,754 $2,748,180 +$603,436 $2.11 27
2026 Q1 1,024,763 $1,866,248 +$49,660 $1.82 24
2025 Q4 986,261 $1,903,480 +$401,694 $1.93 27
2025 Q3 1,008,943 $2,119,104 +$213,669 $2.10 20
2025 Q2 904,332 $2,161,971 +$184,723 $2.39 23
2025 Q1 827,009 $2,390,767 +$140,067 $2.89 24
2024 Q4 777,224 $2,425,644 +$424,115 $3.12 25
2024 Q3 640,359 $2,075,180 +$1,982,603 $3.24 21
2024 Q2 26,602 $8,947 +$8,947 $0.34 4
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .